We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19.
- Authors
Sasso, Bruna Lo; Gambino, Caterina Maria; Scichilone, Nicola; Giglio, Rosaria Vincenza; Bivona, Giulia; Scazzone, Concetta; Muratore, Roberto; Milano, Salvatore; Barbagallo, Mario; Agnello, Luisa; Ciaccio, Marcello
- Abstract
Objective The aim of the study was to assess the role of midregional proadrenomedullin (MR-proADM) in patients with COVID-19. Methods We included 110 patients hospitalized for COVID-19. Biochemical biomarkers, including MR-proADM, were measured at admission. The association of plasma MR-proADM levels with COVID-19 severity, defined as a requirement for mechanical ventilation or in-hospital mortality, was evaluated. Results Patients showed increased levels of MR-proADM. In addition, MR-proADM was higher in patients who died during hospitalization than in patients who survived (median, 2.59 nmol/L; interquartile range, 2.3–2.95 vs median, 0.82 nmol/L; interquartile range, 0.57–1.03; P <.0001). Receiver operating characteristic curve analysis showed good accuracy of MR-proADM for predicting mortality. A MR-proADM value of 1.73 nmol/L was established as the best cutoff value, with 90% sensitivity and 95% specificity (P <.0001). Conclusion We found that MR-proADM could represent a prognostic biomarker of COVID-19.
- Subjects
ITALY; BIOMARKERS; REVERSE transcriptase polymerase chain reaction; STATISTICS; COVID-19; SCIENTIFIC observation; CONFIDENCE intervals; RETROSPECTIVE studies; ARTIFICIAL respiration; HOSPITAL mortality; DESCRIPTIVE statistics; PEPTIDE hormones; POLYMERASE chain reaction; RECEIVER operating characteristic curves; ODDS ratio; DATA analysis; DATA analysis software
- Publication
Laboratory Medicine, 2021, Vol 52, Issue 5, p493
- ISSN
0007-5027
- Publication type
Article
- DOI
10.1093/labmed/lmab032